Table 3 Details of the sensitivity analyses.

From: Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients

Sensitivity analysis

GLP-1 RA (n)

SGLT-2 inhibitor (n)

Comparison

RR

95% CI

I2 (%)

P-value

For obese participants with T2DM

Without CREDENCE (limiting primary outcomes)

30,760

21,873

GLP-1 RA vs. placebo

0.88

0.82–0.95

26

0.20

   

SGLT-2 inhibitor vs. placebo

0.94

0.85–1.03

  
   

GLP-1 RA vs. SGLT-2 inhibitor

0.94

0.83–1.06

  

Without REWIND

26,177

24,239

GLP-1 RA vs. placebo

0.89

0.81–0.98

37

0.11

   

SGLT-2 inhibitor vs. placebo

0.91

0.83–1.00

  
   

GLP-1 RA vs. SGLT-2 inhibitor

0.98

0.86–1.12

  

Liraglutide and subcutaneous semaglutide

3,969

24,239

GLP-1 RA vs. placebo

0.83

0.70–0.99

42

0.13

   

SGLT-2 inhibitor vs. placebo

0.91

0.82–1.01

  
   

GLP-1 RA vs. SGLT-2 inhibitor

0.91

0.75–1.11

  

Daily GLP-1 RA

9,028

24,239

GLP-1 RA vs. placebo

0.93

0.78–1.10

55

0.038

   

SGLT-2 inhibitor vs. placebo

0.91

0.81–1.02

  
   

GLP-1 RA vs. SGLT-2 inhibitor

1.02

0.83–1.25

  

Weekly GLP-1 RA

21,732

24,239

GLP-1 RA vs. placebo

0.87

0.78–0.95

30

0.19

   

SGLT-2 inhibitor vs. placebo

0.91

0.84–1.00

  
   

GLP-1 RA vs. SGLT-2 inhibitor

0.95

0.83–1.08

  

For non-obese participants with T2DM

Without CREDENCE (limiting primary outcomes)

21,992

15,591

GLP-1 RA vs. placebo

0.88

0.79–0.98

50

0.037

   

SGLT-2 inhibitor vs. placebo

0.91

0.80–1.04

  
   

GLP-1 RA vs. SGLT-2 inhibitor

0.97

0.81–1.15

  

Without REWIND

16,675

17,617

GLP-1 RA vs. placebo

0.86

0.76–0.98

49

0.040

   

SGLT-2 inhibitor vs. placebo

0.90

0.79–1.02

  
   

GLP-1 RA vs. SGLT-2 inhibitor

0.93

0.75–1.16

  

Liraglutide and subcutaneous semaglutide

2,339

17,617

GLP-1 RA vs. placebo

0.84

0.66–1.07

56

0.047

   

SGLT-2 inhibitor vs. placebo

0.90

0.78–1.03

  
   

GLP-1 RA vs. SGLT-2 inhibitor

0.94

0.71–1.24

  

Daily GLP-1 RA

6,519

17,617

GLP-1 RA vs. placebo

0.94

0.81–1.09

29

0.21

   

SGLT-2 inhibitor vs. placebo

0.90

0.81–1.01

  
   

GLP-1 RA vs. SGLT-2 inhibitor

1.04

0.87–1.25

  

Weekly GLP-1 RA

15,473

17,617

GLP-1 RA vs. placebo

0.85

0.73–0.98

53

0.039

   

SGLT-2 inhibitor vs. placebo

0.90

0.79–1.03

  
   

GLP-1 RA vs. SGLT-2 inhibitor

0.94

0.77–1.14

  
  1. SGLT2i, sodium-glucose cotransporter-2 inhibitor; GLP-1 RA, glucagon-like peptide-1 receptor agonist; RR, relative risk; CI, confidence interval.
Back to article page